Headline
The latest stories from AHA Today.
Ten years from now, more than half of middle-income Americans aged 75 and older with mobility limitations or high health care and functional needs will not be able to afford to live in an independent- or assisted-living community or nursing home.
The Centers for Disease Control and Prevention yesterday reported 695 cases of measles, the most since the virus was eliminated in the U.S. in 2000.
The Centers for Medicare & Medicaid Services today encouraged governors and state Medicaid directors to partner with the agency to better integrate care for beneficiaries eligible for both Medicare and Medicaid.
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices.
The Montana legislature last week passed legislation funding Medicaid coverage for low-income adults for six more years.
The Centers for Medicare & Medicaid Services late today issued a proposed rule that would increase Medicare inpatient prospective payment system rates by a net 3.2 percent in FY 2020, compared to FY 2019, for hospitals that are meaningful users of electronic health records and submit quality…
Under the proposed rule, payments would increase by $37 million as compared to fiscal year 2019. CMS also estimates that site-neutral cases will continue to decrease as a proportion of total cases, and will account for 29 percent of all LTCH cases in FY 2020.
The AHA and American Association for Physician Leadership today released Leadership Evolve, a collection of digital resources on dyad leadership and workforce wellness to spark collaboration within organizations and across the health care field.
The proportion of hospital emergency department visits by uninsured patients declined 2.1 percentage points per year between 2014 and 2016, just after the health insurance exchanges opened and states began expanding Medicaid under the Affordable Care Act.
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years.